COMPASS THERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
COMPASS THERAPEUTICS, INC. (CMPX) reported Earnings Per Share, Basic and Diluted of -$0.07 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-09.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-09
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$0.07.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$0.15.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.10.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.07.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$1.31.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$0.96.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2020 was -$0.01.
- COMPASS THERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2019 was -$5.19.
| Period end | Earnings Per Share, Basic and Diluted 0 month | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|
| 2022-03-31 | -$0.07 10-Q · filed 2022-05-09 | -$0.22 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$0.31 derived: net income ÷ weighted average shares · filed 2023-11-09 | -$1.09 derived: net income ÷ weighted average shares · filed 2023-11-09 | ||
| 2021-12-31 | -$0.15 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$0.26 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.12 derived: net income ÷ weighted average shares · filed 2023-03-15 | -$1.31 10-K · filed 2022-03-18 | ||
| 2021-09-30 | -$0.10 10-Q · filed 2021-11-12 | -$1.09 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$1.26 10-Q · filed 2021-11-12 | |||
| 2021-06-30 | -$1.07 10-Q · filed 2021-08-16 | -$1.23 10-Q · filed 2021-08-16 | ||||
| 2021-03-31 | -$0.14 10-Q · filed 2022-05-09 | -$0.31 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.49 derived: net income ÷ weighted average shares · filed 2022-11-09 | -$0.73 derived: net income ÷ weighted average shares · filed 2022-11-09 | ||
| 2020-12-31 | -$0.16 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$0.34 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$0.60 derived: net income ÷ weighted average shares · filed 2022-03-18 | -$0.96 10-K · filed 2022-03-18 | ||
| 2020-09-30 | -$0.18 10-Q · filed 2021-11-12 | -$0.46 derived: net income ÷ weighted average shares · filed 2021-11-12 | -$0.88 10-Q · filed 2021-11-12 | -$1.10 derived: net income ÷ weighted average shares · filed 2021-11-12 | ||
| 2020-06-30 | -$0.41 10-Q · filed 2021-08-16 | -$1.16 10-Q · filed 2021-08-16 | -$1.40 derived: net income ÷ weighted average shares · filed 2021-08-16 | -$2.53 derived: net income ÷ weighted average shares · filed 2021-08-16 | ||
| 2020-03-31 | -$0.90 10-Q · filed 2021-04-30 | -$1.06 derived: net income ÷ weighted average shares · filed 2021-04-30 | -$2.38 derived: net income ÷ weighted average shares · filed 2021-04-30 | -$0.01 10-K · filed 2020-06-08 | ||
| 2019-12-31 | $0.00 10-Q · filed 2020-02-14 | -$1.46 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$0.01 10-Q · filed 2020-02-14 | -$5.19 10-K · filed 2021-03-05 | ||
| 2019-09-30 | -$1.27 10-Q · filed 2020-11-09 | $0.00 10-Q · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | -$4.26 10-Q · filed 2020-11-09 | -$4.82 derived: net income ÷ weighted average shares · filed 2020-11-09 | |
| 2019-06-30 | -$1.33 10-Q · filed 2020-08-13 | $0.00 10-Q · filed 2019-08-13 | -$3.00 10-Q · filed 2020-08-13 | -$3.54 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$3.63 derived: net income ÷ weighted average shares · filed 2020-11-09 | |
| 2019-03-31 | -$2.15 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$2.16 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$2.16 derived: net income ÷ weighted average shares · filed 2020-11-09 | -$0.01 10-K · filed 2020-06-08 | ||
| 2018-12-31 | $0.00 10-Q · filed 2020-02-14 | -$0.00 derived: net income ÷ weighted average shares · filed 2020-02-14 | -$0.01 10-Q · filed 2020-02-14 | |||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-13 | $0.00 10-Q · filed 2019-11-13 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-13 | |||||
| 2018-03-31 | -$0.01 10-K · filed 2019-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |